IP Library Granted Patent US 7,767,232
Granted Patent B2
US 7,767,232 · App. 10/663,693 · Granted Aug 3, 2010

Control of nitric oxide bioactivity by perfluorocarbons

Assignee: New York University
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,767,232
App. No.
10/663,693
Granted
Aug 3, 2010
Kind
B2
Abstract

Perfluorocarbons are used to control nitric oxide metabolism, either to inhibit nitric oxide activity or to potentiate the effects of nitric oxide. Perfluorocarbons can be used, for example, to treat hypotension and vasoplegia in septic shock, to protect against myocardial ischemia-reperfusion injury, to treat hypertension, and to provide antiplatelet effects.

Claims (16)

1. A method for controlling metabolism of nitric oxide comprising administrating to an animal in need thereof effective amount of a perfluorocarbon having a molecular weight of from about 400 Dalton to about 700 Dalton, wherein said animal is suffering from at least one disease or condition selected from the group consisting of hypotension, vasoplegia, vasoconstriction, vasorelaxation, thrombosis, blood clotting endotoxic shock and septic shock, restenosis after angioplasty, ischemic perfusion injury and preeclampsia.

2. The method according to claim 1 wherein the perfluorocarbon is administered in an amount of at least about 0.5% w/volume of blood to inhibit nitric oxide activity.

3. The method according to claim 1 wherein the perfluorocarbon is administered in an amount of less than about 0.5% w/volume of blood to enhance nitric oxide activity.

4. The method according to claim 3 wherein the perfluorocarbon is administered in an amount of from about 0.01% to about 0.1% w/volume of blood to enhance nitric oxide activity.

5. The method according to claim 3 wherein at least one nucleophile is administered in conjunction with the perfluorocarbon.

6. The method according to claim 5 wherein the nucleophile is a thiol or mixture of thiols.

7. The method according to claim 6 wherein the thiol is α-lipoic acid, L-cysteine, or glutathione.

8. The method according to claim 2 comprising treating hypotension and vasoplegia.

9. The method according to claim 3 comprising treating vasorelaxation.

10. The method according to claim 3 comprising treating blood clotting and thrombosis.

11. The method according to claim 3 comprising suppressing restenosis after angioplasty.

12. The method according to claim 3 comprising treating preeclampsia.

13. A method for treating microbial or viral infections comprising administering to an animal in need thereof an effective amount of a perfluorocarbon and an optional nucleophile.

14. The method according to claim 13 wherein the viral infections are selected from the group consisting of rhinoviral infections and retroviral infections.

15. A method for treating leukemia comprising administering an effective amount of a perfluorocarbon to a patient in need thereof.

16. The method according to claim 1 wherein the perfluorocarbon is in an emulsion, wherein the particle size of the perfluorocarbon ranges from about 25 nm to about 1 micron.

Assignments (2)
CONFIRMATORY LICENSE Recorded Apr 17, 2018
From: NEW YORK UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 045559/0560 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2005
From: NUDLER, EVGENY; RAFIKOV, RUSLAN; RAFIKOVA, OLGA
To: NEW YORK UNIVERSITY
Reel/Frame 016935/0881 →
Continuity (2)
Provisional Application 6041182800 · Sep 19, 2002
Related Publication 20040127425A1 · Jul 1, 2004